1 Min Read
Jan 5 (Reuters) - Orexigen Therapeutics Inc :
* Anticipates filing of new drug submission for contrave with Health Canada by partner, Valeant Canada in Q1 2017 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.